Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
---|---|---|---|---|---|---|
RARE | Ultragenyx Pharmaceutical Inc. | EVP & Chief Commercial Officer | $3.61M | -$256K | -6.63% | Mar 1, 2024 |
DNLI | Denali Therapeutics Inc. | Director | $348K | May 31, 2024 | ||
INZY | Inozyme Pharma, Inc. | Director | Oct 3, 2024 |
Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
---|